Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (NQ: ENSC )

0.6704 +0.0347 (+5.46%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ensysce Biosciences Inc

< Previous 1 2 3 4 Next >
Ensysce Biosciences Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Via ACCESSWIRE
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
Via ACCESSWIRE
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
Via ACCESSWIRE
Ensysce Biosciences Receives Notice from Nasdaq
Via ACCESSWIRE
Ensysce Biosciences Presenting at Upcoming Meetings
Via ACCESSWIRE
Ensysce Biosciences Submits Phase 3 Protocol to the FDA
Via ACCESSWIRE
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
Via ACCESSWIRE
Ensysce Biosciences Announces IRB Approval for Key MPAR Study
Via ACCESSWIRE
Ensysce Biosciences Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
Via ACCESSWIRE
Ensysce Biosciences Provides Mid-Year 2024 Update
Via ACCESSWIRE
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
Via ACCESSWIRE
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
Via ACCESSWIRE
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Via ACCESSWIRE
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE
Ensysce Biosciences Regains Compliance with Nasdaq
Via ACCESSWIRE
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
Via ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
Via ACCESSWIRE
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Via ACCESSWIRE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
Via ACCESSWIRE
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
Via ACCESSWIRE
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Via ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Via ACCESSWIRE
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.